


Accepted Manuscript

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

James F. Donohue, Paul W. Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, David G. Morris, Francesco Patalano, Robert Fogel



PII: S1094-5539(17)30237-7

DOI: [10.1016/j.pupt.2017.12.005](https://doi.org/10.1016/j.pupt.2017.12.005)

Reference: YPUPT 1690

To appear in: *Pulmonary Pharmacology & Therapeutics*

Received Date: 24 September 2017

Revised Date: 6 December 2017

Accepted Date: 15 December 2017

Please cite this article as: Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Morris DG, Patalano F, Fogel R, Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease, *Pulmonary Pharmacology & Therapeutics* (2018), doi: 10.1016/j.pupt.2017.12.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Correlations between FEV1 and Patient-Reported Outcomes: a Pooled Analysis of 23 Clinical Trials in Patients with Chronic Obstructive Pulmonary Disease

James F Donohue^{a*}, Paul W Jones^b, Christian Bartels^c, Jessica Marvel^d, Peter D'Andrea^d, Donald Banerji^d, David G Morris^c, Francesco Patalano^c, Robert Fogel^d

Author Details:

^aDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA. ^bDivision of Clinical Science, St George's, University of London, London, UK. ^cNovartis Pharma AG, Basel, Switzerland. ^dNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

***Correspondence:** James F. Donohue, MD, FCCP, Department of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, CB# 7020, 130 Mason Farm Rd, Chapel Hill, NC 27599; e-mail: jdonohue@med.unc.edu

Portions of the data have been presented in poster format at the Population Approach Group Europe Congress, June 2-5, 2015, Crete Greece, and in abstract form at ERS 2015, September 26-30, Amsterdam, Holland (Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Patalano F and Fogel R. *European Respiratory Journal* 2015;46[suppl 59] DOI: 10.1183/13993003.congress-2015.PA1013) and CHEST 2015, October 24-28, 2015, Montreal, Canada (Donohue JF, Bartels C, Patalano F, Marvel J, D'Andrea P, Banerji D and Fogel R. *Chest*. 2015;148[4_MeetingAbstracts]:719A).

Figures/Tables: 3 figures/2 tables; plus 2 supplementary figures/4 supplementary tables

Download English Version:

<https://daneshyari.com/en/article/8537752>

Download Persian Version:

<https://daneshyari.com/article/8537752>

[Daneshyari.com](https://daneshyari.com)